** Shares of drug developer Entrada Therapeutics TRDA.O rise 7.4% to $14 premarket
** TRDA says FDA has removed clinical hold on co's therapy, ENTR-601-44, which is being studied for a type of muscle-wasting disorder called Duschenne muscular dystrophy (DMD) in the U.S.
** Co receives authorization to initiate early-stage trial
** In December 2022, the FDA placed a clinical hold on co's application to start trials of the therapy
** Co plans to begin study enrollment in H1 2026
** In the last 12 months, TRDA has fallen ~2%
(Reporting by Siddhi Mahatole)
((Siddhiprabhanjan.mahatole@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。